Trial Profile
A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Lucerastat (Primary)
- Indications Fabry's disease
- Focus Registrational; Therapeutic Use
- Acronyms MODIFY
- Sponsors Idorsia Pharmaceuticals
- 11 Oct 2021 Results presented in the Idorsia Pharmaceuticals Media Release.
- 11 Oct 2021 Primary endpoint has not been met. (Change from baseline to Month 6 in the modified Brief Pain Inventory-Short Form 3 (BPI-SF3) score of neuropathic pain at its worst in the last 24 hours), according to an Idorsia Pharmaceuticals media release.
- 16 Sep 2021 Status changed from active, no longer recruiting to completed.